Cellular immunotherapy licensed for advanced prostate cancer

Traynor, Kate
June 2010
American Journal of Health-System Pharmacy;6/1/2010, Vol. 67 Issue 11, p862
Academic Journal
The article reports that the U.S. Food and Drug Administration (FDA) has approved the used of cellular immunotherapy in the treatment of prostate cancer. It mentions that FDA approved the use of sipuleucel- T, or Provenge, for the treatment of prostate cancer that is resistant to standard hormonal therapy. Provenge will be available to oncologists and urologists at the hospitals that participated in clinical trials of the cellular immunotherapy product.


Related Articles

  • FDA Rejects Promising Prostate Cancer Drug. Faloon, William // Life Extension;Sep2007, Vol. 13 Issue 9, p7 

    The authors reflect on the decision of the U.S. Food and Drug Administration (FDA) to prohibit the use of the immune-boosting vaccine Provenge despite its efficacy shown in a controlled clinical trial. The government believed that advanced prostate cancer patients must not risk using any drug...

  • GTx Submits Clinical Hold Complete Response Letter To FDA For Its Planned Phase II Clinical Study Of Capesaris(r) For Secondary Hormonal Therapy of Advanced Prostate Cancer.  // Biomedical Market Newsletter;4/7/2012, Vol. 21, p1 

    The article informs that GTx Corp. has submitted a complete letter to the U.S.-based Food and Drug Administration (FDA) in response to its announcement regarding company's clinical hold on the clinical trials of capesaris. It further informs that capesaris is used for secondary hormonal therapy...

  • Panel recommends RCTs for prostate cancer treatments. McCARTY, MARK // Medical Device Daily;12/15/2009, Vol. 13 Issue 240, p1 

    The article focuses on a statement by a panel from the U.S. Food and Drug Administration (FDA) that randomized clinical trials (RCTs) are necessary for devices used in the treatment of prostate cancer. This was despite physicians' claims of difficulty in finding enrollees to the RCTs. According...

  • GTx Announces Clinical Hold on Clinical Trials Evaluating Capesaris(r) for First and Second Line Treatments of Advanced Prostate Cancer.  // Biomedical Market Newsletter;2/21/2012, Vol. 21, p1 

    The article informs that the U.S. Food & Drug Administration (FDA) has notified GTx Inc. that it has placed a clinical hold on the company's clinical trials evaluating Capesaris (GTx-758) for primary androgen deprivation therapy for advanced prostate cancer and secondary hormonal treatment. A...

  • Emerging novel therapies in the treatment of castrate-resistant prostate cancer. Abdulla, Alym; Kapoor, Anil // Canadian Urological Association Journal;Apr2011, Vol. 5 Issue 2, p120 

    The treatment options for patients with castration-resistant prostate cancer (CRPC), until very recently, only included docetaxel. In the past 10 months, newly Federal Drug Administration (FDA) approved agents in the United States have shown survival benefit for patients with CRPC. This review...

  • Exelixis to Initiate Cabozantinib '306 Trial with Pain Endpoint in mCRPC.  // Biomedical Market Newsletter;10/31/2011, Vol. 21, p43 

    The article reports on the move of Exelixis Inc. to initiate the '306 trial, the first phase 3 pivotal trial of cabozantinib in patients with metastatic castration-resistant prostate cancer (CRPC) in the U.S. It mentions that the Food and Drug Administration (FDA) asserts that the trial can be...

  • FDA Approves Trial of Adamis Pharmaceuticals Product Candidate to Treat Prostate Cancer.  // Biomedical Market Newsletter;6/9/2011, p84 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of Adamis Pharmaceuticals Corp.'s investigational new drug (IND) application for its APC-100 prostate cancer (PCa) treatment. It states that the company plans to start its Phase 1/2a clinical studies of APC-100 in...

  • Immunotherapy data may signal new era in advanced PCa care. Kerr, Richard R. // Urology Times;6/1/2009, Vol. 37 Issue 7, p6 

    The article reports on the study of sipuleucel-T agent as an experimental form of immonutherapy for androgen-independent prostate cancer in Chicago, Illinois. Accordingly, the agent could change the paradigm for treating the cancer if approved by the Food and Drug Administration (FDA). In...

  • Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Sharma, Padmanee; Wagner, Klaus; Wolchok, Jedd D.; Allison, James P. // Nature Reviews Cancer;Nov2011, Vol. 11 Issue 11, p805 

    The US Food and Drug Administration (FDA) recently approved two novel immunotherapy agents, sipuleucel-T and ipilimumab, which showed a survival benefit for patients with metastatic prostate cancer and melanoma, respectively. The mechanisms by which these agents provideclinical benefit are not...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics